What are the latest figures on the hepatitis d market’s size and projected CAGR?
The hepatitis D market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to limited treatment options, high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.
The hepatitis D market size is expected to see steady growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to expansion of reimbursement policies for novel therapies, and rising investment in the healthcare sector, rising adoption of combination treatments, increasing hepatitis B vaccination coverage, and growing public health initiatives. Major trends in the forecast period include advancements in molecular diagnostic tools, shift toward personalized medicine for liver disease management, development of novel RNA-based therapies, expansion of clinical trials for hepatitis D treatments, and use of telemedicine for hepatitis management.
Get Your Free Sample of The Global Hepatitis D Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21202&type=smp
Which Market drivers have played a significant role in driving the hepatitis d market?
The increasing prevalence of hepatitis B is expected to propel the growth of the hepatitis D market going forward. Hepatitis B refers to a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increase in Hepatitis B cases is attributed to factors such as unprotected sexual contact, sharing of needles, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D relies on the Hepatitis B virus for its replication, as it uses the surface antigen of Hepatitis B to infect liver cells, making the co-infection of both viruses a critical factor in the progression of liver disease. For instance, in November 2023, according to the Department of Health and Human Services, a US-based government department, in 2022, newly reported chronic hepatitis B cases rose by 11% compared to 2021. Therefore, the increasing prevalence of hepatitis B is driving the growth of the hepatitis D market.
What are the key segments within the hepatitis d market?
The hepatitis d market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Diagnosis: Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Other Diagnosis
3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online Pharmacies
4) By End-Users: Clinic, Hospital, Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D, Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D, Decompensated Chronic Hepatitis D
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/hepatitis-d-global-market-report
Which key players are shaping the hepatitis d market?
Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, Biorex Diagnostics Ltd.
Which transformative trends will shape the hepatitis d market landscape?
Major companies operating in the hepatitis D market are focusing on introducing innovative formulations such as recombinant vaccines to enhance immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines refer to vaccines produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, to produce the protein, which is then used to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. The approval also extends to preventing hepatitis D, as it is caused by the delta agent, which cannot occur without a hepatitis B infection. The approval is based on positive results from two pivotal Phase 3 clinical studies, protect and constant, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen engerix-B vaccine.
How do regional factors impact the hepatitis d market, and which region is the largest contributor?
North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Hepatitis D Market Report 2025 Offer?
The hepatitis d market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Hepatitis D, also known as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is considered the most severe form of viral hepatitis and occurs only in individuals who are already infected with the hepatitis B virus (HBV). Hepatitis D virus depends on hepatitis B virus for its replication and survival, making it a co-infection or superinfection.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21202
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
